Medicenna Therapeutics (MDNA) Competitors C$1.10 -0.02 (-1.79%) As of 08/22/2025 03:57 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock MDNA vs. VBV, CUS, AIM, ITH, FRX, IPA, APM, CRDL, GXE, and GPHShould you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Aimia (AIM), International Tower Hill Mines (ITH), Fennec Pharmaceuticals (FRX), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Cardiol Therapeutics (CRDL), Gear Energy (GXE), and Graphite One (GPH). These companies are all part of the "pharmaceutical products" industry. Medicenna Therapeutics vs. Its Competitors VBI Vaccines Chemtrade Electrochem Inc, Aimia International Tower Hill Mines Fennec Pharmaceuticals ImmunoPrecise Antibodies Andean Precious Metals Cardiol Therapeutics Gear Energy Graphite One VBI Vaccines (TSE:VBV) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations. Which has stronger earnings & valuation, VBV or MDNA? Medicenna Therapeutics has lower revenue, but higher earnings than VBI Vaccines. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVBI VaccinesC$3.36M0.00-C$62.16M-C$0.97N/AMedicenna TherapeuticsC$4.87K16,904.27-C$25.98M-C$0.36-3.03 Does the media prefer VBV or MDNA? In the previous week, VBI Vaccines' average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score. Company Overall Sentiment VBI Vaccines Neutral Medicenna Therapeutics Neutral Do insiders & institutionals have more ownership in VBV or MDNA? 13.0% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is VBV or MDNA more profitable? VBI Vaccines has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. VBI Vaccines' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VBI VaccinesN/A N/A N/A Medicenna Therapeutics -533,640.00%-159.88%-32.80% SummaryMedicenna Therapeutics beats VBI Vaccines on 5 of the 9 factors compared between the two stocks. Get Medicenna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDNA vs. The Competition Export to ExcelMetricMedicenna TherapeuticsBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$82.30MC$137.09MC$5.76BC$6.37BDividend YieldN/A3.74%4.41%6.72%P/E Ratio-3.033.8731.1073.11Price / Sales16,904.274,057.33433.451,702.25Price / Cash1.1513.1937.7383.29Price / Book4.2246.309.534.90Net Income-C$25.98M-C$90.99MC$3.26BC$301.20M7 Day Performance1.85%0.41%2.10%1.35%1 Month Performance29.41%3.50%2.81%1.88%1 Year Performance-48.84%205.45%30.56%27.39% Medicenna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDNAMedicenna TherapeuticsN/AC$1.10-1.8%N/A-47.9%C$82.30MC$4.87K-3.0320VBVVBI VaccinesN/AN/AN/AN/AC$308.86MC$3.36M-4.9722CUSChemtrade Electrochem Inc,N/AN/AN/AN/AC$306.50MN/A0.0060AIMAimia1.3062 of 5 starsC$3.18-0.9%C$4.00+25.8%+29.0%C$305.84MC$464.71M-3.9120News CoverageITHInternational Tower Hill MinesN/AC$1.70+1.8%N/A+171.8%C$238.67MN/A-71.02220FRXFennec PharmaceuticalsN/AC$11.45+2.2%N/A+53.8%C$220.81MC$34.86M-193.9610IPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownAPMAndean Precious Metals2.5478 of 5 starsC$1.29+7.5%C$2.00+55.0%+22.9%C$135.47MC$154.78M2.5530CRDLCardiol TherapeuticsN/AC$1.58-1.3%N/A-41.3%C$131.11MN/A-3.1120News CoverageGXEGear EnergyN/AN/AN/AN/AC$126.52MC$134.93M10.391,310GPHGraphite OneN/AC$0.82-1.2%N/A+3.8%C$83.03MN/A-11.7920News Coverage Related Companies and Tools Related Companies VBI Vaccines Alternatives Chemtrade Electrochem Inc, Alternatives Aimia Alternatives International Tower Hill Mines Alternatives Fennec Pharmaceuticals Alternatives ImmunoPrecise Antibodies Alternatives Andean Precious Metals Alternatives Cardiol Therapeutics Alternatives Gear Energy Alternatives Graphite One Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:MDNA) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access